---
document_datetime: 2023-09-21 17:28:07
document_pages: 50
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/nimenrix-h-c-2226-p46-0048-epar-assessment-report_en.pdf
document_name: nimenrix-h-c-2226-p46-0048-epar-assessment-report_en.pdf
version: success
processing_time: 63.2035882
conversion_datetime: 2025-12-28 02:17:05.138267
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 January 2016 EMA/105851/2016 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report for paediatric studies submitted according to Article 46 of the Regulation (EC) No 1901/2006

## Nimenrix

International non-proprietary name: meningococcal group A, C, W135 and Y conjugate vaccine

Procedure No. EMEA/H/C/002226/P46 048

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Final assessment report for paediatric studies submitted in accordance with article 46 of regulation (EC) No 1901/2006, as amended

Nimenrix International non-proprietary name: MENINGOCOCCAL GROUP A, C, W135 AND Y CONJUGATE VACCINE Procedure no.: EMA/H/C/2226/P46 048

Marketing authorisation holder (MAH): GSK Biologicals

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Introduction............................................................................................7                  |
|-------------------------------------------------------------------------------------------------------------------------------|
| 2. Scientific discussion ................................................................................7                    |
| 2.1. Information on the development program...............................................................7                   |
| 2.2. Clinical aspects....................................................................................................9    |
| 2.2.1. Introduction .....................................................................................................9    |
| 2.2.2. Clinical study....................................................................................................9    |
| 2.2.3. Discussion on clinical aspects............................................................................ 48          |
| 3. Rapporteur's overall conclusion and recommendation .......................... 48                                           |
| Fulfilled:................................................................................................................ 48 |
| Not fulfilled:........................................................................................................... 48  |
| 4. Additional clarification requested.......................................................... 49                            |

<div style=\"page-break-after: always\"></div>

Keportrimal

|                  | LISTOFABBREVIATIONS                                                                                                                                                                                                          |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10Pn-PD-DiT      | GSKBiologicalsliquid10-valentpneumococcal conjugatevaccinewithproteinD,diphtheriaand tetanus toxoids asproteincarriers and containingpneumococcal serotypes1,4,5,6B.7F,9V,14,18C,19Fand23F, referredinthedocumentasSynflorix |
| AE               | AdverseEvent                                                                                                                                                                                                                 |
| ANOVA            | AnalysisofVariance                                                                                                                                                                                                           |
| ATP              | According-To-Protocol                                                                                                                                                                                                        |
| BCG              | Bacille Calmette-Guerin                                                                                                                                                                                                      |
| CDC              | CentersforDisease Control andPreventionUnitedStates                                                                                                                                                                          |
| CI               | ConfidenceInterval                                                                                                                                                                                                           |
| CLIA             | ChemiluminescentImmunoassay                                                                                                                                                                                                  |
| CRM197           | Anon-toxicmutantformofCorynebacteriumdiphtheria toxin                                                                                                                                                                        |
| CRO              | ContractResearch Organization                                                                                                                                                                                                |
| DoB              | Date of Birth                                                                                                                                                                                                                |
| D                | Diphtheria                                                                                                                                                                                                                   |
|                  | Diphtheria Toxoid                                                                                                                                                                                                            |
| DTPa-HBV-IPV/Hib | CombinedDiphtheria-tetanus-acellularpertussis-hepatitis B-inactivatedpoliovirus-Haemophilusinfluenzaetypeb vaccine,refered throughout the documentasDTPa-HBV- IPV/HiborInfanrixhexa                                          |
| EBV              | EpsteinBarrVirus                                                                                                                                                                                                             |
| eCRF             | electronicCaseReportForm                                                                                                                                                                                                     |
| ELISA            | Enzyme-LinkedImmunosorbentAssay                                                                                                                                                                                              |
| ER               | EmergencyRoom                                                                                                                                                                                                                |
| ESFU             | Extended Safety Follow-Up                                                                                                                                                                                                    |
| EU               | EuropeanUnion                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| FDA           | FoodandDrugAdministration,UnitedStates                                            |
|---------------|-----------------------------------------------------------------------------------|
| FHA           | Filamentous Haemagglutinin                                                        |
| GCP           | Good ClinicalPractice                                                             |
| GMC           | GeometricMeanConcentration                                                        |
| GMIT          | GeometricMeanTitre                                                                |
| GBS           | Guillain-Barre Syndrome                                                           |
| GSK           | GlaxoSmithKline                                                                   |
| HBs           | HepatitisBSurface antigen                                                         |
| hSBA          | SerumBactericidalAssay/Activityusinghuman complement                              |
| hSBA-MenA     | Serumbactericidalactivityagainst N.meningitidis serogroupAusinghumancomplement    |
| hSBA-MIenC    | SerumbactericidalactivityagainstN.meningitidis serogroupCusinghumancomplement     |
| hSBA-MenW-135 | SerumbactericidalactivityagainstN.meningilidis serogroupW-135usinghumancomplement |
| hSBA-MenY     | Serumbactericidalactivity against N.meningitidis serogroupYusinghumancomplement   |
| ICF           | Informed ConsentForm                                                              |
| ICH           | IntermationalConferenceonHarmonization                                            |
| IEC           | IndependentEthics Committee                                                       |
| IMI           | Intramuscular                                                                     |
| IMD           | ImmuneMediatedDisease                                                             |
| IRB           | InstitutionalReviewBoard                                                          |
| IU            | IntemationalUnits                                                                 |
| LAR           | LegallyAcceptableRepresentative                                                   |
| MedDRA        | MedicalDictionaryforRegulatoryActivities                                          |
| MenA          | NeisseriameningitidisserogroupA                                                   |
| MenACWY-TT    | GSKBiologicalsmeningococcal serogroups A,C,W-                                     |

135.Y tetanus toxoidconjugatevaccine

<div style=\"page-break-after: always\"></div>

| MenC          | NeisseriameningitidisserogroupC                                                                                               |
|---------------|-------------------------------------------------------------------------------------------------------------------------------|
| MenW-135      | NeisseriameningitidisserogroupW-135                                                                                           |
| MenY          | NeisseriameningitidisserogroupY                                                                                               |
| MNIR          | Measles,Mumps andRubella                                                                                                      |
| MMRY          | Measles,Mumps,Rubella and Varicella                                                                                           |
| NOCI          | New Onset of Chronic Illness(es)                                                                                              |
| OPA           | OpsonophagocytoticActivity                                                                                                    |
| PD            | ProteinD,a 42kDcell-surfacelipoproteinwhichishighly conservedamongcapsulatedandunencapsulatedstrains ofHaemophilusinfluenzae. |
| PHE           | PublicHealthEngland                                                                                                           |
| PRN           | Pertactin                                                                                                                     |
| PRP           | Polyribosyl Ribitol Phosphate                                                                                                 |
| PS            | Polysaccharide                                                                                                                |
| PT            | Pertussis Toxoid                                                                                                              |
| RDE           | RemoteDataEntry                                                                                                               |
| rSBA          | SerumBactericidalAssay/Activityusingrabbit complement                                                                         |
| rSBA-MIenA    | Serumbactericidal activity against N.meningitidis serogroupA (usingrabbitcomplement)                                          |
| rSBA-MenC     | Serumbactericidalactivityagainst N.meningitidis serogroupCusingrabbitcomplement                                               |
| rSBA-MenW-135 | Serumbactericidal activity against N.meningitidis serogroupW-135usingrabbitcomplement                                         |
| rSBA-MenY     | Serumbactericidal activity against N.meningitidis serogroupYusingrabbitcomplement                                             |
| RSV           | RespiratorySyncitialVirus                                                                                                     |
| SAE           | SeriousAdverseEvent                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 1. Introduction

On 7 th  October 2015, the MAH submitted a completed paediatric study for Nimenrix, in accordance with Article 46 of Regulation (EC) No1901/2006, as amended.

These data are also submitted as part of the Paediatric Investigation Plan, as agreed with the Paediatric Committee

A short critical expert overview has also been provided.

## 2. Scientific discussion

## 2.1. Information on the development program

Nimenrix is a quadrivalent meningococcal polysaccharide conjugate vaccine composed of the capsular polysaccharides of Neisseria meningitidis serogroups A, C, W-135 and Y, each conjugated to tetanus toxoid.

Nimenrix was authorised via the centralised procedure on 20th April 2012 for active immunisation of individuals from the age of 12 months and above against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y. A single dose is used for immunisation from one year on.

Nimenrix bears the following indication (taken from the SPC):

## 4.1 Therapeuticindications

Nimenrixisindicatedfor activeimmunisationofindividualsfrom the age of12monthsand above against invasive meningococcal diseases caused by Neisseria meningiidis group A, C, W-135 and Y.

Nimenrix bears the following posology (taken from the SPC):

## 4.2 Posologyandmethodofadministration

Posology

Nimenrixshouldbeusedin accordancewith availableofficialrecommendations.

Primaryvaccination:

Asingle O.5ml doseofthereconstitutedvaccineisusedforimmunisation.

Boostervaccination:

Nimenrix maybe given in subjects who have previously been vaccinated with a plain polysaccharide meningococcalvaccine(seesections4.4and5.1).

Paediatricpopulation

Thesafety and efficacy of Nimenrix in childrenunder 12 months of age hasnot yet been established. No data are available.

<div style=\"page-break-after: always\"></div>

## Methodofadministration

Immunisation shouldbe carried out by intramuscular injection only,preferably into the deltoid muscle.

In children12to23monthsof age,thevaccinemay alsobe administeredinthe anterolateralpart of the thigh (seesections 4.4 and 4.5).

Forinstructions onreconstitution of themedicinal product before administration,seesection6.6.

As agreed with the PDCO for the Nimenrix Paediatric Investigation Plan, the company has conducted a study to assess the use of Nimenrix in subjects below 12 months of age.

The company now submits the clinical study report for study MenACWY-TT-083 (EudraCT number: 2009-016841-24) in accordance with Article 46 of Regulation (EC) No 1901/2006.

Study MenACWY -TT -083 evaluates a 2-dose and a 3-dose MenACWY -TT primary vaccination schedule in infancy « 12 months). The study was conducted in Germany, Spain and Estonia.

The company states that:

- the submitted study is part of a clinical development program and that it intends to submit a type II variation (within 18 months) to include the MenACWY-TT-083 study results in the product information, proposing to extend the indication to infants below one year of age.
- in accordance with Article 16(2) of Regulation (EC) No 726/2004, the data submitted do not influence the benefit-risk balance for the above mentioned product and therefore do not require taking further regulatory action on the marketing authorisation for the above mentioned product.

•

GSK Biologicals' pneumococcal conjugate vaccine (Synflorix) is also administered in the study.

An article 46 application for this vaccine is being sent in parallel to the European Medicines Agency.

CHMP comment:

no additional comment

<div style=\"page-break-after: always\"></div>

## 2.2. Clinical aspects

## 2.2.1. Introduction

The company now submits the clinical study report for study MenACWY-TT-083 (EudraCT number: 2009-016841-24) in accordance with Article 46 of Regulation (EC) No 1901/2006.

## 2.2.2. Clinical study

Study title : Immunogenicity and safety of GSK Biologicals' meningococcal vaccine (GSK 134612) when co-administered with a pneumococcal conjugate vaccine and Infanrix hexa in healthy infants.

Study code

: 113369 (MenACWY-TT-083)

EUDRACT Number

: 2009-016841-24

A phase III, open, multi-country, randomized, controlled study with four parallel groups

Study initiation date: 01 July 2010

Study completion date: 10-September-2013

Data lock point (Date of database freeze): 21-August-2015

Date of report: Final: 11 September 2015

The duration of the study was about 16 months for each subject.

## The company states:

- the study protocol, any amendments, the informed consent, and other information that required pre-approval were reviewed and approved by a national, regional, or investigational centre IEC or IRB.
- overall this study was conducted in accordance with \"good clinical practice\" (GCP) and all applicable regulatory requirements, including the Declaration of Helsinki.

## Methods

## · Study participants

## Inclusion criteria

- A male or female between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination
- Born after a gestation period of at least 36 weeks

<div style=\"page-break-after: always\"></div>

## Exclusion criteria

- History of / inter-current diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b disease, pneumococcal and/or meningococcal disease.
- Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitides serogroups A, C, W-135 or Y with the exception of vaccines where the first dose could be given within the first two weeks of life according to the national recommendations (for example hepatitis B and BCG).
- Use of registered or non-registered products, as described, including immunosuppressants and immunoglobulins
- History of hypersensitivity that may be aggravated by vaccine
- Chronic disease / acute disease at time of administration

A total of 2095 subjects were enrolled in this study.

## CHMP comment : the inclusion / exclusion criteria are acceptable

## · Treatments

Subjects were assigned to one of four groups:

- i. Group ACWY\\_3: subjects received three primary vaccination doses of MenACWY-TT vaccine at 2, 3 and 4 months of age and one booster dose of MenACWY-TT vaccine at 12 months of age.
- ii. Group ACWY\\_2: subjects received two primary vaccination doses of MenACWY-TT vaccine at 2 and 4 months of age and one booster dose of MenACWY-TT vaccine at 12 months of age.
- iii. Group MenCCRM: subjects received two primary vaccination doses of Menjugate vaccine at 2 and 4 months of age and one booster dose of Menjugate vaccine at 12 months of age (active control group).
- iv. Group MenC-TT: subjects received two primary vaccination doses of NeisVac-C vaccine at 2 and 4 months of age and one booster dose of NeisVac-C vaccine at 12 months of age (active control group).

One dose of study vaccine MenACWY-TT or of one of the control vaccines (Menjugate or NeisVac-C) were to be administered according to the randomized assignment intramuscularly in the anterolateral muscle of the left thigh.

In addition, all subjects were vaccinated with Infanrix hexa and Synflorix at 2, 3, 4 and 12 months of age. Infanrix hexa and Synflorix were to be administered IM in the upper and lower anterolateral muscle of the right thigh, respectively.

For the current product, MenACWY-TT, the following formulation, presentation and lot numbers were used:

<!-- image -->

| Vaccine    | Formulation                                                                                                                                                         | Presentation (Volume')                                           | LotNumber(diluent lotnumber)                            |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------|
| MenACWY-TT | MenA-TT conjugate5ug;MenC-TT conjugate 5ug;MenW-TT  conjugate 5ug; MenY-TT conjugate 5μg; Tetanus toxoid (total) ~44μg; Tris-HCL, pH 6.8+/-0.3 1.6 mM; Sucrose 28mg | Lyophilizedpellet tobereconstituted with saline diluent (0.5 ml) | AMECA006C AMECA005A AMECA011B1 (AD02B328B) (AD02B262B2） |

<div style=\"page-break-after: always\"></div>

The following pages of this report describe the co-administered vaccines.

Synflorix (EU/1/09/508/006-7-8) [active subjstance: pneumococcal polysaccharide serotype 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, 23f] was authorised on 30 th  March 2009.

The following formulation, presentation and lot numbers were used:

<!-- image -->

| Vaccine                                                  | Formulation                                                                                                                                                                                                                                                                                                                                         | Presentation (Volume)                 | LotNumber           |
|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|---------------------|
| GSKBiologicals' 10-valent Pn-PD- DiT vaccine (Synflorix) | ProteinDcarrier:1ugofeachPSfor serotypes1,5,6B,7F,9V,14and23Fand3 μgforserotype4conjugated toPD. Tetanustoxoidcarrier:3μugofcapsularPS ofserotypes18Cconjugated toTT. Diphtheriatoxoid:3ugofcapsularPSof serotype19Fconjugated toDT. Protein carrier content: ~12 μg PD, ~4.5 μg DT,~7μgTT 0.5 mg aluminium (Al3+) as aluminium phosphate adjuvant. | Whitish liquid in a syringe. (0.5 ml) | ASPNA031E ASPNA060F |

Infanrix hexa (EU/1/00/152/001-8 &amp; -21) [active substance: diphtheria toxoid / tetanus toxoid / Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) / hepatitis B surface antigen / poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain)) / Haemophilus influenzae type-b polysaccharide] was authorised on 23 rd Oct 2000.

The following formulation, presentation and lot numbers were used:

<!-- image -->

Menjugate (Novartis), UK PL 13767/0023, licensed on 21 st  April 2004, is meningococcal group C conjugate vaccine. Menjugate has been the subject of an outgoing MRP (UK/H/0375/003) with UK as RMS and CMSs: AT, BE, DE, DK, GR, ES, FI, FR, IS, IE, IT, LU, NL, NO, PT &amp; SE.

Active substance: Neisseria meningitidis group C (strain C11) oligosaccharide conjugated to Corynebacterium diphtheriae CRM197 protein and adsorbed on aluminium hydroxide. The product is marketed as Mejugate Kit.

The following formulation, presentation and lot numbers were used:

<!-- image -->

<div style=\"page-break-after: always\"></div>

Neis-Vac C (Baxter, acquired by Pfizer in 2014) UK PL 00057/1517, authorised on 18 th  July 2000. With UK as RMS, this product has been the subject of an MRP (UK/H/0435/001) with the following CMSs: AT, BE, DK, FI, FR, DE, GR, IE, IT, LU, NL, PT, ES, SE &amp; NO.

Active substance: Neisseria meningitidis group C (strain C11) polysaccharide (de-Oacetylated)conjugated to tetanus toxoid and adsorbed on aluminium hydroxide, hydrated.

The following formulation, presentation and lot numbers were used:

<!-- image -->

CHMP comment : all vaccines appear to have been administered within their terms of licence and / or within an acceptable clinical investigation framework.

The dosage and administration of the study vaccines are presented in Table 6:

Table 6 Dosageand administration

<!-- image -->

| Type of contact and time point   |   Dose | Treatment Group   | Vaccine/Product   | Route 1   | Site 2   | Side 3   |
|----------------------------------|--------|-------------------|-------------------|-----------|----------|----------|
| Visit 1 (Day 0)                  |      1 | ACWY_3            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 1 (Day 0)                  |      1 | ACWY_2            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 1 (Day 0)                  |      1 | MenCCRM           | MenC-CRM          | IM        | Ant T    | L        |
| Visit 1 (Day 0)                  |      1 | MenC-TT           | MenC-TT           | IM        | Ant T    | L        |
| Visit 1 (Day 0)                  |      1 | All groups        | Infanix hexa      | IM        | U Ant T  | R        |
| Visit 1 (Day 0)                  |      1 | All groups        | Synflorix         | IM        | L Ant T  | R        |
| Visit 2 (Month 1)                |      2 | ACWY_3            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 2 (Month 1)                |      2 | All groups        | Infanrix hexa     | IM        | U Ant T  | R        |
| Visit 2 (Month 1)                |      2 | All groups        | Synflorix         | IM        | L Ant T  | R        |
| Visit 3 (Month 2)                |      3 | ACWY 3            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 3 (Month 2)                |      2 | ACWY 2            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 3 (Month 2)                |      2 | MenCCRM           | MenC-CRM          | IM        | Ant T    |          |
| Visit 3 (Month 2)                |      2 | MenC-TT           | MenC-TT           | IM        | Ant T    | L        |
| Visit 3 (Month 2)                |      3 | All groups        | Infanrix hexa     | IM        | U Ant T  | R        |
| Visit 3 (Month 2)                |      3 | All groups        | Synflorix         | IM        | L Ant T  | R        |
| Visit 5 (Month 10)               |      4 | ACWY_3            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 5 (Month 10)               |      3 | ACWY_2            | MenACWY-TT        | IM        | Ant T    | L        |
| Visit 5 (Month 10)               |      3 | MenCCRM           | MenC-CRM          | IM        | Ant T    | L        |
| Visit 5 (Month 10)               |      3 | MenC-TT           | MenC-TT           | IM        | Ant T    | L        |
| Visit 5 (Month 10)               |      4 | All groups        | Infanrix hexa     | IM        | U Ant T  | R        |
| Visit 5 (Month 10)               |      4 | All groups        | Synflorix         | IM        | L Ant T  | R        |

The vaccine recipients were observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of a rare anaphylactic reaction following the administration of vaccine(s)/product(s).

CHMP comment : all vaccines appear to have been administered with appropriate caution.

## · Objectives

Overall: to demonstrate the non-inferiority of the immune response to Nimenrix when given intramuscularly at 2, 4 and 12 months of age or given at 2, 3, 4 and 12 months of age compared to licensed products Menjugate or NeisVac-C given intramuscularly at 2, 4 and 12 months of age.

<div style=\"page-break-after: always\"></div>

## Primary objectives:

The following co-primary objectives were to be assessed in a hierarchical manner according to the order presented below.

1. To demonstrate at 5 months of age (Visit 4) the non-inferiority of the 3-dose schedule of MenACWY-TT conjugate vaccine compared to the 2-dose schedule of the MenC-CRM197 conjugate vaccine in terms of percentage of subjects with post-primary vaccination serum bactericidal activity against N. meningitidis serogroup C using rabbit complement (rSBA-MenC) antibody titre greater than or equal to 1:8.

Criteria: the lower limit of the two-sided standardized asymptotic 95% Confidence Interval (CI) for the group difference (ACWY\\_3 minus MenCCRM) in the percentage of subjects with post-primary vaccination rSBA-MenC titre ≥ 1:8 is greater than or equal to the pre-defined clinical limit of -5%.

2. To demonstrate at 5 months of age (Visit 4) the non-inferiority of the 3-dose schedule of the MenACWY-TT conjugate vaccine compared to the 2-dose schedule of the MenC-TT conjugate vaccine in terms of percentage of subjects with post-primary vaccination rSBA-MenC antibody titre greater than or equal to 1:8.

Criteria: the lower limit of the two-sided standardized asymptotic 95% CI for the group difference (ACWY\\_3 minus MenC-TT) in the percentage of subjects with post-primary vaccination rSBA-MenC titre ≥ 1:8 is greater than or equal to the predefined clinical limit of -5%.

3. To demonstrate at 5 months of age (Visit 4) the immunogenicity of the 3-dose schedule for MenACWY-TT for serogroups A, W-135 and Y.

Criteria: the lower limit of the two-sided exact 95% CI for the percentage of subjects with postprimary vaccination rSBA antibody titre ≥ 1:8 in the ACWY\\_3 group is greater than or equal to the pre-defined clinical limit of 80%.

4. To demonstrate at 5 months of age (Visit 4) the non-inferiority of the 2-dose schedule of the MenACWY-TT conjugate vaccine compared to the 2-dose schedule of the MenC-CRM197 conjugate vaccine in terms of percentage of subjects with postprimary vaccination rSBA-MenC antibody greater than or equal to 1:8.

Criteria: the lower limit of the two-sided standardized asymptotic 95% CI for the group difference (ACWY\\_2 minus MenCCRM) in the percentage of subjects with post-primary vaccination rSBA-MenC titre ≥ 1:8 is greater than or equal to the predefined clinical limit of -5%.

5. To demonstrate at 5 months of age (Visit 4) the non-inferiority of the 2-dose schedule of the MenACWY-TT conjugate vaccine compared to the 2-dose schedule of the MenC-TT conjugate vaccine in terms of percentage of subjects with postprimary vaccination rSBA-MenC antibody titre greater than or equal to 1:8.

Criteria: the lower limit of the two-sided standardized asymptotic 95% CI for the group difference (ACWY\\_2 minus MenC-TT) in the percentage of subjects with postprimary vaccination rSBA-MenC titre ≥ 1:8 is greater than or equal to the predefined clinical limit of -5%.

<div style=\"page-break-after: always\"></div>

6. To demonstrate at 5 months of age (Visit 4) the immunogenicity of the 2-dose schedule for MenACWY-TT for serogroups A, W-135 and Y.

Criteria: the lower limit of the two-sided exact 95% CI for the percentage of subjects with postprimary vaccination rSBA antibody titre ≥ 1:8 in the ACWY\\_2 group is greater than or equal to the pre-defined clinical limit of 80%.

## Secondary objectives:

- To evaluate immunogenicity of serogroups A, C, W-135 and Y, Infanrix hexa and Synflorix
- To evaluate the safety and reactogenicity of the investigational vaccine.

## CHMP comment: the objectives are acceptable

## · Study design

A phase III, open, multi-country, randomized, controlled study with four parallel groups

## Criteria for non-inferiority:

- the lower limit of the two-sided standardized asymptotic 95% CI for the group difference in the percentage of subjects with post-primary vaccination rSBA-MenC titre ≥ 1:8 is greater than or equal  -5% (objectives 1, 2, 4 and 5).
- the lower limit of the two-sided exact 95% CI for the percentage of subjects with post-primary vaccination rSBA antibody titre ≥ 1:8 greater than or equal to 80%.

## CHMP comment:

Discussion on the choice of the pre-defined clinical limits for declaring non-inferiority cannot be found.

The statistical analysis plan has not been included in the documentation.

[Issues may be pursued via the forthcoming variation procedure].

<div style=\"page-break-after: always\"></div>

## · Outcomes/endpoints

## Laboratory assays and time-points

A volume of at least 6 ml (or 7ml, depending on the time point) of whole blood to provide a minimum of 3 ml (respectively 3.2 ml) of serum was to be drawn from all subjects at prevaccination (Day 0), one month after the last priming vaccination (Month 3), pre-booster (Month 10) and post-booster (Month 11). After centrifugation, serum samples were to be kept at -20°C until shipment to the Sponsor.

Table 7 provides an overview of the laboratory assays used for sample testing:

Table7 HumoralImmunity（Antibodydetermination)

<!-- image -->

| Component                                                  | Method              | Kit/Manufacturer   | Unit                  |   Cut-off | Laboratory            |
|------------------------------------------------------------|---------------------|--------------------|-----------------------|-----------|-----------------------|
| NeisseriameningitidisSerogroup AL103125Ab                  | rSBA                | NA                 | 1/dilution            |     4     | Public Health England |
| NeisseriameningitidisSerogroup CL3vC11Ab                   | rSBA                | NA                 | 1/dilution            |     4     | PublicHealth England  |
| NeisseriameningitidisSerogroup WL3vMP01240070Ab            | rSBA                | NA                 | 1/dilution            |     4     | PublicHealth England  |
| NeisseriameningitidisSerogroup YL3vS1975Ab                 | rSBA                | NA                 | 1/dlution             |     4     | PublicHealth England  |
| NeisseriameningitidisSerogroup AL103125Ab                  | hSBA                | NA                 | 1/dilution            |     4     | GSK Biologicals       |
| NeisseriameningitidisSerogroup CL3vC11Ab                   | hSBA                | NA                 | 1/dilution            |     4     | GSK Biologicals       |
| NeisseriameningitidisSerogroup WL3vMP01240070Ab            | hSBA                | NA                 | 1/dilution            |     4     | GSK Biologicals       |
| NeisseriameningitidisSerogroup YL3vS1975Ab                 | hSBA                | NA                 | 1/dilution            |     4     | GSK Biologicals       |
| Clostridiumtetani.TetanusToxoid Ab.IgG                     | ELISA ormultiplex   | NA                 | IU/ml                 |     0.1   | GSK Biologicals       |
| Corynebacterium dphtheriae.DiphtheriaToxoid Ab.IqG         | ELISA ormultiplex   | NA                 | IU/ml                 |     0.1   | GSK Biologicals       |
| Corynebacterium dphtheriae.DiphtheriaToxoidAb              | Seroneutralisation' | NA                 | IU/ml                 |     0.016 | GSK Biologicals       |
| Hepatitis BVirus.Surface Ab                                | CLIA\"               | NA                 | mlU/ml                |     6.2   | GSK Biologicals       |
| PoliovirusSabinType 1Ab                                    | Seroneutralisation  | NA                 | End point dilution50% |     8     | GSKBiologicals        |
| PoliovirusSabin Type2Ab                                    | Seroneutralisation  | NA                 | End point dllution50% |     8     | GSKBiologicals        |
| PoliovirusSabinType3Ab                                     | Seroneutralisation  | NA                 | Endpoint dllution50%  |     8     | GSK Biologicals       |
| Bordetellapertussis.Pertussis ToxinAb.IgG                  | ELISA or multiplex  | NA                 | EL.U/ml               |     5     | GSK Biologicals       |
| Bordetelapertussis.Filamentous HemagutininAb.IgG           | ELISA ormultiplex   | NA                 | EL.U/ml               |     5     | GSK Biologicals       |
| Bordetellapertussis.Pertactin Ab.lgG                       | ELISA ormultiplex   | NA                 | EL.U/ml               |     5     | GSK Biologicals       |
| Haemophiusinfluenzeatype b.Polyribosyl RibitolPhosphate Ab | ELISA ormultiplex   | NA                 | μg/ml                 |     0.15  | GSK Biologicals       |
| Streptococcus pneumoniae.Polysaccharide01 Ab.IqG           | ELISA               | NA                 | μg/ml                 |     0.15  | Goldblatt             |
| Slreptococcus pneumoniae.Polysaccharide04 Ab.lgG           | ELISA               | NA                 | μg/ml                 |     0.15  | Goldblatt             |
| Streptococcus pneumoniae.Polysaccharide05 Ab.lqG           | ELISA               | NA                 | μg/ml                 |     0.15  | Goldblatt             |
| Streptococcus pneumoniae.Polysaccharide06B                 | ELISA               | NA                 | ng/ml                 |     0.15  | Goldblatt             |
| Ab.IgG Streptococcus pneumoniae.Polysaccharide07F          | ELISA               | NA                 | μg/ml                 |     0.15  | Goldblatt             |

<div style=\"page-break-after: always\"></div>

| Component                                         | Method   | Kit/Manufacturer   | Unit   | Cut-off   | Laboratory   |
|---------------------------------------------------|----------|--------------------|--------|-----------|--------------|
| Ab.IgG                                            |          |                    |        |           |              |
| Streptococcus pneumoniae.Polysaccharide0gv Ab.IqG | ELISA    | NA                 | μg/ml  | 0.15      | Goldblatt    |
| Streptococcus pneumoniae.Polysaccharide14 Ab.IgG  | ELISA    | NA                 | μg/ml  | 0.15      | Goldblatt    |
| Streptococcus pneumoniae.Polysaccharide18c Ab.IqG | ELISA    | NA                 | μg/ml  | 0.15      | Goldblatt    |
| Streptococcus pneumoniae.Polysaccharide19F Ab.IgG | ELISA    | NA                 | μg/ml  | 0.15      | Goldblatt    |
| Streptococcus pneumoniae.Polysaccharide23F Ab.IgG | ELISA    | NA                 | μg/ml  | 0.15      | Goldblatt    |

<!-- image -->

The laboratories that performed testing for this study are listed in Table 8:

## Table8 Clinicallaboratories

| Laboratory                                                              | Address                                                                                                                                                                                | Testing                                                                                                       |
|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Public Health England                                                   | PublicHealthLaboratory,Manchester ManchesterMedical MicrobiologyPartnership POBox209,2ndFloor,ClinicalSciencesBuildingIl ManchesterRoyal Infirmary, Oxford Road, Manchester, M139WZ-UK | SBA-MenA,SBA-MenC rSBA-MenW-135andrSBA- MenY                                                                  |
| GSKBiologicals Global Vaccine Clinical Laboratory, Rixensart            | BiospecimenReception-B7/44 Rue deInstitut,89-B-1330Rixensart-Belgium                                                                                                                   | hSBA-MenC,hSBA-MenY, anti-TT,anti-D, anti-DVero- cell neutralisation,anti-PT, anti-FHA,anti-PRN and anti- PRP |
| GSKBiologicalsGlobal Vaccine Clinical Laboratory, Laval Canada          | BiospecimenReception-Clinical Serology 525Cartier blvd West-Laval-Quebec-Canada- H7V3S8                                                                                                | hSBA-MenAandhSBA- MenW-135                                                                                    |
| GSK Biologicals Global Vaccine Clinical Laboratory, Wavre-NordNoirEpine | AvenueFleming,20-B-1300Wavre-Belgium                                                                                                                                                   | Anti-HBs,anti-polio1,2,and 3.                                                                                 |
| GOLDBLATT                                                               | UniversityCollege of London Instituteof Child Health 30Guilford Street London,WC1N1EH-UK                                                                                               | ELISAforpneumococcal serotypes1,4,5,6B,7F 9V,14,18C,19Fand23F                                                 |

Detailsregarding clinical laboratoriesused fortesting of anti-poliovirusresponseswillbeprovidedin anannexreport.

<div style=\"page-break-after: always\"></div>

## Statistical Methods

## · Study population /Sample size

The target sample size was 1650 subjects evaluable for immunogenicity (412 subjects per vaccine group). Considering that approximately 20% of the enrolled subjects might have withdrawn or not been evaluable for immunogenicity, the target sample size to be enrolled was 2060 subjects (515 subjects per vaccine group).

The global power to meet all primary objectives considering a sample size of 412 evaluable subjects per group was at least 82.3%.

A total of 2095 subjects were enrolled in this study.

Six cohorts were defined for analysis:

## 1) Primary Total Vaccinated cohort

The Primary Total Vaccinated cohort included all vaccinated subjects during the primary phase. Thus, the Primary Total Vaccinated cohort for safety included all subjects with at least one dose of primary vaccine administration documented and the Primary Total Vaccinated cohort for immunogenicity included vaccinated subjects from primary phase for whom data concerning postprimary immunogenicity endpoint measures were available. The Total Vaccinated cohort analysis was performed per treatment actually administered.

## 2) Primary ATP (according to protocol) cohort for safety

The Primary ATP cohort for safety included all eligible subjects during the primary vaccination phase:

- who met all inclusion criteria and no exclusion criteria for the study,
- who had received at least one dose of study vaccine/control according to their random assignment during the primary vaccination course,
- for whom administration site of study vaccine/control was known,
- who had not received a vaccine not specified or forbidden in the protocol during the primary vaccination phase.

## 3) Primary ATP cohort for immunogenicity

The Primary ATP cohort for immunogenicity included all evaluable subjects from the Primary ATP cohort for safety:

- who did not receive forbidden medications as defined in the protocol;
- who had no intercurrent medical condition which might have influenced the immune response;
- who complied with the vaccination schedule for Visits 1, 2 and 3 defined in the protocol;
- who complied with the blood sample schedule for Visit 4. The interval between vaccination at Visit 3 and blood sample at Visit 4 for inclusion in the ATP cohort for immunogenicity was defined as 21 to 48 days.

<div style=\"page-break-after: always\"></div>

## 4) Booster Total Vaccinated cohort

The Booster Total Vaccinated cohort included all subjects who received a booster dose at Visit 5. Thus, the Booster Total Vaccinated cohort for safety included all subjects from the primary phase with a booster dose administration documented and the Booster Total Vaccinated cohort for immunogenicity included all subjects who received a booster dose and for whom data concerning post-booster immunogenicity endpoint measures were available. The Booster Total Vaccinated cohort analysis was performed per treatment actually administered in the primary epoch.

## 5) Booster ATP cohort for safety

The Booster ATP cohort for safety included all eligible subjects during the booster phase of the study:

- who met all inclusion criteria and no exclusion criteria for the study;
- who had received three (for the ACWY\\_3 group) or two (for the ACWY\\_2, MenCCRM and MenC-TT groups) vaccine doses in the primary vaccination phase;
- who had received the booster vaccine dose;
- who had not received a vaccine not specified or forbidden in the protocol (subjects who received a vaccine not foreseen by the study protocol from 30 days before until 30 days after the study vaccine dose were eliminated from the Primary ATP cohort for safety if the vaccine not foreseen by the protocol was administered before the post-booster vaccination blood sample).

## 6) Booster ATP cohort for immunogenicity

The Booster ATP cohort for immunogenicity included all evaluable subjects from the booster ATP cohort for safety:

- who did not receive forbidden medications as defined in the protocol;
- who had no intercurrent medical condition which might have influenced the immune response;
- who complied with the vaccination schedule for Visit 5;
- who complied with the blood sample schedule for Visit 6. The interval between vaccination at Visit 5 and blood sample at Visit 6 for inclusion in the booster ATP cohort for immunogenicity was defined as 21 to 48 days.

<div style=\"page-break-after: always\"></div>

## · Randomisation

Randomisation was performed at GSK Biologicals, Rixensart, using MATEX, a program developed for use in SAS® (Cary, NC, USA) by GSK Biologicals.

A treatment number uniquely identified the vaccine doses to be administered to the same subject.

A randomization block scheme was used for creating the randomization list to ensure that correct balance between treatments was maintained.

The transfer of supplies was tracked in the central randomization system.

The treatment allocation at the investigator site was performed using a central randomisation system on internet (SBIR). The randomisation algorithm used a minimisation procedure accounting for centre. After having checked the eligibility of the subject, the site staff in charge of the vaccination accessed the randomisation system on internet. Upon providing the subject identification number, the randomisation system used the minimisation algorithm to determine the treatment number to be used for the subject. Each treatment number had to be recorded in the eCRF on the Vaccine Administration screen (Randomisation/Treatment Allocation Section).

## Randomisation of subjects to assay subsets

All subjects were to be tested at post-primary vaccination, pre-booster and post-booster time points for the four meningococcal serogroups A, C, W-135 and Y by rSBA. In addition to this, for the other assays and time points, the subjects were randomised so that some assays were performed on subsets:

- At pre-vaccination, 50% of the subjects in the ACWY\\_3 and ACWY\\_2 groups were to be tested for rSBA-MenA and rSBA-MenC titres, the other 50% were to be tested for rSBA-MenW-135 and rSBA-MenY titres. In the MenCCRM and MenC-TT groups, 50% of the subjects were to be tested for rSBA-MenC titres and 25% of them were to be tested for rSBA-MenA, rSBA-MenW-135 and rSBAMenY titres.
- At all time points, 50% of subjects of all groups were to be tested for hSBA titres for each of the four serogroups present in the MenACWY-TT vaccine.
- At all time points, 25% of the subjects of all groups were to be tested for antipneumococcal antibody concentrations by ELISA assay. The other 25% were to be tested for antibody concentrations/titres against the antigens present in the DTPa-IPV-HBV/Hib vaccine.

Subjects in each group were randomly allocated to Subset 1, 2, 3, 4, 5 and 6, as shown:

<!-- image -->

| Group   | Subset1   | Subset2   | Subset3   | Subset4   | Subset5   | Subset6   |
|---------|-----------|-----------|-----------|-----------|-----------|-----------|
| ACWY3   | 25%       | 25%       | 25%       | 25%       |           |           |
| ACWY2   | 25%       | 25%       | 25%       | 25%       |           |           |
| MenCCRM | 25%       | 25%       |           |           | 25%       | 25%       |
| MenC-TT | 25%       | 25%       |           |           | 25%       | 25%       |

<div style=\"page-break-after: always\"></div>

## Subset1:

- rSBA-MenACatpre-vaccination
- hSBA-MenACatalltimepoints
- Subset 2:
- rSBA-MenWYatpre-vaccination
- hSBA-MenWYatall timepoints
- Subset 3:
- rSBA-MenACatpre-vaccination
- hSBA-MenAC atall timepoints
- 10pneumococcal serotypesat all timepoints.
- Subset4:
- rSBA-MenWYatpre-vaccination
- hSBA-MenWYat all timepoints
- Anti-TT,anti-D,anti-FHA,anti-PT,anti-PRN,anti-HBs,anti-PRPandantipolio1,2.3atalltimepoints
- Subset5:
- rSBA-MenCatpre-vaccination
- hSBA-MenACatall timepoints
- 10pneumococcalserotypesatalltimepoints.
- Subset6:
- hSBA-MenWYatall timepoints
- Anti-TT,anti-D,anti-FHA,anti-PT,anti-PRN,anti-HBs,anti-PRPandantipolio1,2,3 at all timepoints.

## · Blinding (masking)

This was an open study. A double-blinded design was not feasible due to differences in the presentation of the study vaccines and vaccination schedules across the study groups. blinded to the treatment, and codes were used to link the subject and study (without any link to

Although this was an open-label study, the laboratory in charge of the laboratory testing was the treatment attributed to the subject) to each sample.

The serological data, which would lead to the unblinding of the treatment groups, were not available during the course of the study to any investigator or any person involved in the clinical conduct of the study (including data cleaning).

CHMP comment : The hierarchical testing strategy is appropriate.

In theory, the Applicant should have pre-specified both the ATP cohort and the primary total vaccinated cohort as co-primary in this non-inferiority study. In practice, both were analysed and reached the same conclusion (See Results, below).

<div style=\"page-break-after: always\"></div>

All CIs computed were two-sided 95% CI.

The exact 95% CIs for a proportion within a group were calculated based on the method by Clopper [Clopper, 1934]. The standardised asymptotic 95% CI for the group difference in proportions were based on the method 6 described in paper by Newcombe [Newcombe, 1998]. The 95% CIs for GMTs/GMCs were obtained within each group separately. The 95% CI for the mean of log-transformed titre/concentration was first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs were then obtained by exponential transformation of the 95% CI for the mean of log-transformed titre/concentration.

CHMP comment : The statistical methods are acceptable.

<div style=\"page-break-after: always\"></div>

## Results

- •

## Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

The intervals between study visits are provided in Table 4:

Table4 Intervalsbetweenstudyvisits

| Interval                    | Optimallengthofinterval   | Maximumintervalallowed   |
|-----------------------------|---------------------------|--------------------------|
| DoB→Visit1                  | 60 days                   | 42-90 days2              |
| Visit1→Visit2               | 30days                    | 21-48days2               |
| Visit2→Visit3               | 30days                    | 21-48days2               |
| Visit3→Visit4               | 30days                    | 21-48days2               |
| DoB→Visit53                 | 12months                  | 12-13months 23           |
| Visit5→Visit6               | 30days                    | 21-48 days2              |
| Visit5→PhoneContactorVisit7 | 180days                   | 180-210days              |

Ifasubjectreturned fortheVisit4andlorVisit6blooddrawpriortocompletionof the31-daysafetyfollow-upperiod thesubjectwasinstructed tocontinue torecordthis informationonthediarycarduntil 31 dayspost-vaccinationand mailthediarycardtothesite.The investigatorwasinstructed tomakeanattempttoobtainthisinformationassoon as possibleafterthe31-dayfollow-upperiodifit wasnotmailedin.

## · Conduct of the study

## Protocol amendments

There were 3 amendments to the original protocol dated 27 January 2010.

1. Amendment 1 (06 December 2010): administrative changes
2. Amendment 2 (25 May 2011): the sample size of the study population was increased by about 50% to overcome variability in laboratory results for SBA testing; to support the data obtained by rSBA testing, hSBA testing was also performed; assays for streptococcus pneumoniae opsonophagocytotic activity and antibodies to meningococcal PS were removed based on WHO advice.
3. Amendment 3 (30 July 2012): to allow administration of MMR or MMRV vaccine throughout the study in line with local governmental recommendations to address a measles outbreak in Spain.

The statistical analysis plan was revised to cater for changes in laboratory testing.

CHMP comment : the amendments are noted without further comment.

<div style=\"page-break-after: always\"></div>

ReportFinal

Table23 NumberofsubjectsenrolledintothestudyaswellasthenumberofsubjectsexcludedfromATPanalysesforthe primaryepochwithreasonsforexclusion

<!-- image -->

CHMP comment : the protocol deviations appear to be balanced across the 4 groups. It is considered that the nature and number of deviations would not give rise to any cause for concern over study value.

## Withdrawals

The number of subjects vaccinated, completed and withdrawn and reason for withdrawal is presented in the following table:

|                                                           | ACWY3ACWY2MenCCRMMenC-TTTotal   |     |     |     |      |
|-----------------------------------------------------------|---------------------------------|-----|-----|-----|------|
| Numberof subjectsvaccinatedinPrimaryepoch                 | 528                             | 524 | 516 | 527 | 2095 |
| NumberofsubjectscompletedPrimaryepoch                     | 508                             | 517 | 508 | 509 | 2042 |
| Numberof subjectswithdrawnduringPrimary epoch             | 20                              |     | 8   | 18  | 53   |
| Reasonsforwithdrawal:                                     |                                 |     |     |     |      |
| SeriousAdverseEvent                                       | 7                               | 0   |     | 0   | 3    |
| Non-SeriousAdverse Event                                  | 1                               | 0   | 0   |     |      |
| Protocolviolation                                         | 2                               | 0   |     | 0   | 3    |
| Consentwithdrawal(notduetoan adverseevent)                | 9                               | 5   | 3   | 10  | 27   |
| Migrated/movedfromstudyarea                               | 4                               |     | 2   | 3   | 10   |
| Lost tofollow-up(subjectswithincompletevaccinationcourse) | 2                               | 0   |     | 2   | 5    |
| Lost tofollow-up(subjectswithcompletevaccinationcourse)   | 0                               | 0   | 0   | 0   | 0    |
| Sponsorstudytermination                                   | 0                               | 0   |     | 0   | o    |
| Others                                                    | 0                               |     | 0   | 2   | 3    |

<!-- image -->

Of the 2095 subjects in the Primary Total Vaccinated Cohort, 2042 subjects completed the primary epoch. The main reason for consent withdrawal was; not due to an adverse event, followed by migration from the study area or loss to follow-up.

<div style=\"page-break-after: always\"></div>

## Efficacy results

## · Outcomes and estimation

The first confirmatory primary objective of the study was met as non inferiority of the 3-dose schedule of MenACWY-TT conjugate vaccine versus the 2-dose schedule of MenC-CRM197 conjugate vaccine was demonstrated, since the lower confidence interval limit in the percentage of subjects with post-primary vaccination rSBAMenC titres ≥ 1:8 for ACWY\\_3 group minus MenCCRM group is above -5% (- 1.17%) (Table 41):

Table 41 Differencebetweengroups(ACWY\\_3minusMenCCRM)in percentageofsubjectswithrSBA-MenCtitreequaltoorabove1:8 and1:128,atonemonthpost-primaryvaccinations（PrimaryATP cohortforimmunogenicity)

<!-- image -->

ACWY\\_3=Subjeclswhoreceived3primarydosesofMenACWY-TTat2,3and4monthsofage MenCCRM=Subjectswhoreceived2primarydosesofMenjugateat2and4monthsofage

N=numberofsubjectswithavallableresults

95%CI=Standardizedasymptotic95%confidenceinterval;LL=lowerlimit,UL=upperlimit

The second confirmatory primary objective of the study was met as non inferiority of the 3-dose schedule of MenACWY-TT conjugate vaccine versus the 2-dose schedule of MenC-TT conjugate vaccine was demonstrated, since the lower confidence interval limit in the percentage of subjects with post-primary vaccination rSBAMenC titres ≥ 1:8 for ACWY\\_3 group minus MenC-TT group is above -5% (- 1.57%) (Table 42):

Table42 Differencebetweengroups(AcWY\\_3minusMenC-TT)inpercentage ofsubjectswithrSBA-MenCtitreequaltoorabove1:8and1:128,at onemonthpost-primaryvaccinations（PrimaryATPcohortfor immunogenicity)

<!-- image -->

MenC-TT=Subjects whoreceived 2primary doses of NeisVac-Cat 2and4months of age

ACWY\\_3=Subjectswhoreceived3primarydosesof MenACWY-TTat2,3and4monthsofage

N=numberof subjectswith availableresults

95%Cl=Standardizedasymptotic95%confidence interval;LL=lowerlimit,UL=upperlimit

<div style=\"page-break-after: always\"></div>

The third confirmatory primary objective of the study was met as the immunogenicity of the 3-dose schedule for MenACWY-TT for serogroups A, W-135 and Y was demonstrated, since the lower confidence interval limit of subjects with post-primary vaccination rSBA antibody titres ≥ 1:8 in the ACWY\\_3 group is greater than 80% for each serogroup (98.1%, 97.8% and 90.3%) (Table 43):

<!-- image -->

[  The sixth confirmatory primary objective of the study was met as the immunogenicity of the 2dose schedule for MenACWY-TT for serogroups A, W-135 and Y was demonstrated, since the lower confidence interval limit of subjects with post-primary vaccination rSBA antibody titres ≥ 1:8 in the ACWY\\_2 group is greater than 80% for each serogroup (95.4%, 97.8% and 96.6%) (Table 43, above)  ]

<div style=\"page-break-after: always\"></div>

The fourth confirmatory primary objective of the study was met as non inferiority of the 2-dose schedule of MenACWY-TT conjugate vaccine versus the 2-dose schedule of MenC-CRM197 conjugate vaccine was demonstrated, since the lower confidence interval limit in the percentage of subjects with post-primary vaccination rSBAMenC titres ≥ 1:8 for ACWY\\_2 group minus MenCCRM group is above -5% (- 2.45%) (Table 44):

ReportFinal

Table44 Differencebetweengroups（AcWY\\_2minusMenCCRM)in percentageofsubjectswithrSBA-MenCtitreequaltoorabove1:8 cohortforimmunogenicity)

<!-- image -->

MenCCRM=Subjectswhoreceived 2primary dosesof Menjugate at 2and4monthsof age

ACWY\\_2=Subjectswhoreceived2primary dosesof MenACWY-TTat 2and4months of age

N=numberofsubjectswith availableresults n/%=number/percentageofsubjectswithtitrewithin the specifiedrange

95%Cl=Standardized asymptotic95%confidence interval;LL=lowerlimit,UL=upperlimit

The fifth confirmatory primary objective of the study was met as non inferiority of the 2-dose schedule of MenACWY-TT conjugate vaccine versus the 2-dose schedule of MenC-TT conjugate vaccine was demonstrated, since the lower confidence interval limit in the percentage of subjects with post-primary vaccination rSBAMenC titres ≥ 1:8 for ACWY\\_2 group minus MenC-TT group is above -5% (- 2.84%) (Table 45):

Table45 Differencebetweengroups(AcWY\\_2minusMenC-TT)inpercentage ofsubjectswithrSBA-MenCtitreequaltoorabove1:8and1:128,at onemonthpost-primaryvaccinations（PrimaryATPcohortfor immunogenicity)

<!-- image -->

MenC-TT= Subjects who received 2 primary doses of NeisVac-C at 2 and 4months of age

ACWY\\_2=Subjects who received 2primary doses of MenACWY-TTat 2and4months of age

N=numberofsubjectswithavailableresults n/%=numberlpercentage of subjectswith titrewithin thespecifiedrange

95%CI=Standardized asymptotic95%confidence interval;LL=lowerlimit,UL=upperlimit

<div style=\"page-break-after: always\"></div>

CHMP comment: efficacy results are noted without further comment.

Additional comments on primary objectives by assessor of statistics:

## Results for primary epoch

Difference between groups in percentage of subjects with rSBA-MenC titre equal to or above 1:8 at one month post-primary vaccinations (Objectives 1, 2, 4 and 5)

|     | N                 | n                 | %                 | N                  | n                  | %                  |       | 95% CI   | 95% CI   |
|-----|-------------------|-------------------|-------------------|--------------------|--------------------|--------------------|-------|----------|----------|
|     | 3 dose MenACWY-TT | 3 dose MenACWY-TT | 3 dose MenACWY-TT | 2 dose MenC-CRM197 | 2 dose MenC-CRM197 | 2 dose MenC-CRM197 | %     | LL       | UL       |
| ATP | 461               | 459               | 99.6              | 455                | 453                | 99.6               | 0.01  | -1.17    | 1.2      |
| TV  | 483               | 481               | 99.6              | 481                | 479                | 99.6               | 0     | -1.12    | 1.13     |
|     | 3 dose MenACWY-TT | 3 dose MenACWY-TT | 3 dose MenACWY-TT | 2 dose MenC-TT     | 2 dose MenC-TT     | 2 dose MenC-TT     |       |          |          |
| ATP | 461               | 459               | 99.6              | 457                | 457                | 100                | -0.43 | -1.57    | 0.4      |
| TV  | 483               | 481               | 99.6              | 483                | 483                | 100                | -0.41 | -1.5     | 0.38     |
|     | 2 dose MenACWY-TT | 2 dose MenACWY-TT | 2 dose MenACWY-TT | 2 dose MenC-CRM197 | 2 dose MenC-CRM197 | 2 dose MenC-CRM197 |       |          |          |
| ATP | 456               | 450               | 98.7              | 455                | 453                | 99.6               | -0.88 | -2.45    | 0.43     |
| TV  | 488               | 480               | 98.4              | 481                | 479                | 99.6               | -1.22 | -2.84    | 0.06     |
|     | MenACWY-TT        | MenACWY-TT        | MenACWY-TT        | 2 dose MenC-TT     | 2 dose MenC-TT     | 2 dose MenC-TT     |       |          |          |
| ATP | 456               | 450               | 98.7              | 457                | 457                | 100                | -1.32 | -2.84    | -0.48    |
| TV  | 488               | 480               | 98.4              | 483                | 483                | 100                | -1.64 | -3.2     | -0.83    |

CHMP comment : The six co-primary objectives were met in the ATP and total vaccinated cohorts.

## Secondary objectives

## At one month post-primary vaccination the responses were:

## rSBA:

rSBA titres ≥ 1:128 and GMTs for the ACWY\\_3 and ACWY\\_2 groups:

- The percentage of subjects with rSBA titers ≥ 1:128 in the ACWY\\_3 group ranged from 80.5% (rSBA-MenY) to 94.1% (rSBA-MenW-135).
- The percentage of subjects with rSBA titers ≥ 1:128 in the ACWY\\_2 group ranged from 82.0% (rSBA-MenA) to 95.6% (rSBA-MenW-135).

GMTs ranged from 250.7 for rSBA-MenA to 1120.7 for rSBA-MenW-135 in the ACWY\\_3 group. GMTs ranged from 203.5 for rSBA-MenA to 1605.0 for rSBA-MenW-135 in the ACWY\\_2 group.

rSBA-Men C titres ≥ 1:8 and ≥ 1:128 and GMTs for the MenCCRM and MenC-TT groups:

<div style=\"page-break-after: always\"></div>

- The percentage of subjects with rSBA-MenC titers ≥ 1:8 and ≥ 1:128 was 99.6% and 96.0%, respectively, in the MenCCRM group and 100% and 99.8%, respectively, in the MenC-TT group. GMTs were 957.6 in the MenCCRM group and 1188.1 in the MenC-TT group.

## hSBA:

hSBA titres ≥ 1:8 and GMTs for the ACWY\\_3 and ACWY\\_2 groups:

- The percentage of subjects with hSBA titers ≥ 1:8 in the ACWY\\_3 group ranged from 88.5% (hSBA-MenY) to 99.5% (hSBA-MenC).
- The percentage of subjects with hSBA titers ≥ 1:8 in the ACWY\\_2 group ranged from 96.5% (hSBA-MenA) to 100% (hSBA-MenW-135).

GMTs ranged from 66.5 for hSBA-MenY to 765.6 for hSBA-MenC in the ACWY\\_3 group. GMTs ranged from 157.2 for hSBA-MenA to 1308.3 for hSBA-MenC in the ACWY\\_2 group.

hSBA-MenC titres ≥ 1:8 and GMTs for the MenCCRM and MenC-TT groups:

- The percentage of subjects with hSBA-MenC titers ≥ 1:8 was 100% for both the MenCCRM and the MenC-TT groups.

GMTs were 2626.5 in the MenC-TT group and 3188.1 in the MenCCRM group.

## Infanrix Hexa:

## Anti-D:

The percentage of subjects with anti-D concentrations ≥ 0.1 IU/ml was 100% for all four vaccine groups. The percentage of subjects with anti-D concentrations ≥ 1.0 IU/ml ranged from 84.6% for the ACWY\\_3 group to 94.3% for the MenCCRM group.

GMCs ranged from 2.171 IU/ml in the ACWY\\_3 group to 3.005 IU/ml in the MenCCRM group.

## Anti-TT:

The percentage of subjects with anti-TT concentrations ≥ 0.1 IU/ml was 100% for all four vaccine groups. The percentage of subjects with anti-TT concentrations ≥ 1.0 IU/ml ranged from 95.6% for the ACWY\\_2 group to 99.1% for the MenC-TT group.

GMCs ranged from 2.847 IU/ml in the MenCCRM group to 4.339 IU/ml in the MenC-TT group.

## Anti-PT, FHA and PRN:

All subjects in all four groups had anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/ml.

GMCs ranged from 52.7 EL.U/ml for PT in the ACWY\\_3 group to 149.2 EL.U/ml for FHA in the ACWY\\_2 group.

<div style=\"page-break-after: always\"></div>

## Anti-PT, FHA and PRN vaccine response:

- Vaccine response to the pertussis antigens ranged from 82.4% for FHA in the MenC-TT group to 95.5% for PT in the MenCCRM group.

## Anti-HBs:

The percentage of subjects with anti-HBs concentrations ≥ 10.0 mIU/ml was 98.8% for the ACWY\\_3 and MenC-TT groups and 100% for the ACWY\\_2 and MenCCRM groups. The percentage of subjects with anti-HBs concentrations ≥ 100 mIU/ml ranged from 86.0% for the ACWY\\_3 group to 94.7% for the MenCCRM group.

GMCs ranged from 692.3 mIU/ml in the ACWY\\_3 group to 848.3 mIU/ml in the MenCCRM group.

## Anti-PRP:

The percentage of subjects with anti-PRP concentrations ≥ 0.15 μ g/ml ranged from 98.4% (MenCCRM group) to 100% (ACWY\\_3 and ACWY\\_2 groups). The percentage of subjects with antiPRP concentrations ≥ 1.0 μ g/ml ranged from 76.4% (MenCCRM group) to 93.0% (MenC-TT group).

GMCs ranged from 2.752 μg/ml in the MenCCRM group to 4.662 μg/ml in the MenC-TT group.

## Synflorix:

## Pneumococcal antigens:

One month following the primary vaccination, the percentage of subjects with pneumococcal antibody concentrations ≥ 0.35 μ g/mL was at least 74.0% for all groups and all serotypes.

GMCs ranged from 0.7 μg/ml for serotype 5 in the ACWY\\_2 group to 8.51 μg/ml for serotype 14 in the MenCCRM group.

## Booster phase

At one month post-booster vaccination responses were:

## rSBA:

rSBA titres ≥ 1:8 and ≥ 1:128 and GMTs for the ACWY\\_3 and ACWY\\_2 groups:

The percentage of subjects with rSBA titers ≥ 1:8 and ≥ 1:128 post-booster in the ACWY\\_3 and ACWY\\_2 groups was at least than 99.1% and 95.4%, respectively, for all serogroups.

GMTs ranged from 630.6 for rSBA-MenY to 1955.9 for rSBA-MenW-135 in the ACWY\\_3 group. GMTs ranged from 881.3 for rSBA-MenY to 2777.2 for rSBA-MenW-135 in the ACWY\\_2 group.

rSBA-Men C titres ≥ 1:8 and ≥ 1:128 and GMTs for the MenCCRM and MenC-TT groups:

<div style=\"page-break-after: always\"></div>

The percentage of subjects with rSBA-MenC titers ≥ 1:8 and ≥ 1:128 post-booster was 98.4% and 95.5%, respectively, in the MenCCRM group and 100% and 99.6%, respectively, in the MenC-TT group.

GMTs ranged from 1051.4 in the MenCCRM group to 1960.2 in the MenC-TT group.

## hSBA:

hSBA titres ≥ 1:8 and GMTs for the ACWY\\_3 and ACWY\\_2 groups:

The percentage of subjects with hSBA titers ≥ 1:8 in the ACWY\\_3 and ACWY\\_2 group was greater than 99.0% for all serogroups.

GMTs ranged from 1192.7 for hSBA-MenA to 4411.2 for hSBA-MenC in the ACWY\\_3 group.

GMTs ranged from 1007.2 for hSBA-MenA to 5122.7 for hSBA-MenW-135 in the ACWY\\_2 group.

hSBA-Men C titres ≥ 1:8 and GMTs for the MenCCRM and MenC-TT groups:

The percentage of subjects with hSBA-MenC titers ≥ 1:8 post-booster was 100% in both the MenCCRM and MenC-TT groups.

GMTs were 5438.2 in the MenCCRM group and 5542.3 in the MenC-TT group.

## Infanrix Hexa:

## Anti-D:

The percentage of subjects with anti-D concentrations post-booster ≥ 0.1 IU/ml was 100% for all four vaccine groups. The percentage of subjects with anti-D concentrations ≥ 1.0 IU/ml ranged from 94.6% for the ACWY\\_2 group to 100% for the MenCCRM group.

GMCs ranged from 5.032 IU/ml in the ACWY\\_3 group to 9.078 IU/ml in the MenCCRM group.

## Anti-TT:

The percentage of subjects with anti-TT concentrations post-booster ≥ 0.1 IU/ml was 100% for all four vaccine groups. The percentage of subjects with anti-TT concentrations ≥ 1.0 IU/ml was from 99.2% for the MenCCRM group and 100% for the other three vaccine groups.

GMCs ranged from 8.400 IU/ml in the MenCCRM group to 13.016 IU/ml in the MenC-TT group.

## Anti-PT, FHA and PRN:

All subjects in all four groups had anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/ml.

GMCs ranged from 78.2 EL.U/ml. for PT in the ACWY\\_2 group to 334.3 EL.U/ml. for PRN in the MenC-TT group.

<div style=\"page-break-after: always\"></div>

## Anti-PT, FHA and PRN booster response:

· Booster response to the pertussis antigens ranged from 92.2% for PT in the MenCCRM group to 100% for PRN in the ACWY\\_2 group.

## Anti-HBs:

The percentage of subjects with anti-HBs concentrations ≥ 10.0 mIU/ml was 97.9% for the ACWY\\_3 and 100% for the ACWY\\_2 and MenCCRM and MenC-TT groups. The percentage of subjects with anti-HBs concentrations post-booster ≥ 100 mIU/ml ranged from 95.9% for the ACWY\\_3 group to 100% for the ACWY\\_2 group.

GMCs ranged from 3624.9 mIU/ml in the ACWY\\_3 group to 4866.4 mIU/ml in the MenCCRM group.

## Anti-PRP:

All subjects in all four groups had anti-PRP concentrations ≥ 0.15 μ g/ml. The percentage of subjects with anti-PRP concentrations ≥ 1.0 μ g/ml ranged from 96.6% for the MenC-TT group to 100% for the ACWY\\_2 and MenCCRM groups.

GMCs ranged from 17.350 μg/ml in the ACWY\\_3 group to 23.973 μg/ml in the MenC-TT group.

## Synflorix:

Pneumococcal antigens:

· One month following the booster vaccination, the percentage of subjects with pneumococcal antibody concentrations ≥ 0.35 μ g/mL was at least 91.1% for all groups and all serotypes.

GMCs ranged from 0.84 μg/ml for serotype 5 in the MenC-TT group to 9.75 μg/ml for serotype 14 in the MenCCRM group.

| CHMP comment: efficacy results are noted without further comment.   |
|---------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

## Safety results

## Introduction

All AEs (solicited and unsolicited) starting following administration of each dose of study vaccine/comparator were recorded.

AEs of specific interest for safety monitoring included new onset of chronic illness(es) (e.g. autoimmune disorders, asthma, type I diabetes and allergies).

Occurrences of AEs of specific interest were to be reported up to six months post-booster dose, whether or not they were considered to be possibly related to the treatment administration.

The intensity of each AE and SAE recorded in the eCRF or SAE Report screens, as applicable, was to be assigned to one of the following categories:

| 1 (mild)    | AnAEwhichwaseasilytoleratedbythesubject,causingminimal discomfortandnotinterferingwitheverydayactivities.                                                                                                    |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2(moderate) | AnAEwhichwassufficientlydiscomfortingtointerferewith normaleverydayactivities.                                                                                                                               |
| 3(severe)   | AnAEwhichpreventednormal,everydayactivities imayoungchild,suchanAEwould,forexample,haveprevented attendanceatschool/kindergarten/aday-carecentreandwould havecaused theparent(s)/LAR(s)toseekmedicaladvice). |

The following local (injection-site) AEs were solicited:

<!-- image -->

The following general AEs were solicited:

<!-- image -->

As a consistent method of soliciting AEs, the subject's parent(s)/LAR(s) were asked a non-leading question such as: ' Has your child acted differently or felt different in any way since receiving the vaccine or since the last visit ?'

An 8-day follow-up (Day 0 to Day 7) of solicited AEs was to be performed after each vaccination.

<div style=\"page-break-after: always\"></div>

The intensity of the solicited AEs was to be assessed as described in Table 12:

Table12 Intensityscalesforsolicitedsymptoms

<!-- image -->

Feverwasdefined as:rectal temperature≥38°C/axillary temperature≥37.5°Cloraltemperature≥37.5°C/tympanic temperatureonoralsetting≥37.5°C/tympanictemperatureonrectalsetling≥38°C Thepreferredrouteforrecording temperature in thisstudy wasrectal.

Themaximumintensityoflocalinjectionsiteredness/swellingwasscoredatGSK Biologicals asfollows:

0

None

1*

&gt;0-≤10mm

2

&gt;10mm-≤30mm

3

&gt;30 mm

*Note:Grade1rednessandswellingmeasurement hasbeenchangedto≥0.1-≤10mm. Subjectswhoreportedrednessandswellingwithmeasurement&lt;0.1mmwereconsidered assubjectswithoutrednessorswellingintheanalysis.

## Assessment of causality

The investigator was obligated to assess the relationship between the investigational product and the occurrence of each AE/SAE. The investigator used clinical judgement to determine the relationship.

All solicited local (injection site) reactions were considered causally related to vaccination. Causality of all other AEs was to be assessed by the investigator using the following question:

IsthereareasonablepossibilitythattheAEmayhavebeencausedbytheinvestigational product?

NO

TheAEwasnotcausallyrelated toadministrationof thestudy vaccine(s).Therewereother,morelikelycausesandadministration ofthestudyvaccine(s)wanotsuspectedtohavecontributed tothe AE.

YES

Therewasareasonablepossibilitythatthevaccine(s)contributed to theAE.

Outcome of any non-serious AE within 30 days of vaccination was pro-actively assessed and recorded.

<div style=\"page-break-after: always\"></div>

Safety analysis is divided in the primary phase and the booster phase.

## Primary phase

The analysis of safety was performed on the Primary Total Vaccinated cohort.

## Patient exposure

<!-- image -->

The number and percentage of subjects who received a vaccine dose is presented in Table 361:

<!-- image -->

Of the total number of subjects vaccinated in the primary phase of the study, 96.8% of subjects in the ACWY\\_3 group received all 3 doses of MenACWY-TT and the coadminstered vaccines, 98.7% of subjects in the ACWY\\_2 group received all 2 doses of MenACWY-TT and 98.9% received the coadminstered vaccines, 98.6% of subjects in the MenCCRM group received all 2 doses of Menjugate and the co-adminstered vaccines and 97.0% of subjects in the MenC-TT group received all 2 doses of NeisVac-C and the co-adminstered vaccines.

<div style=\"page-break-after: always\"></div>

Compliance in returning symptom sheets is presented in Table 362:

<!-- image -->

CHMP comment : the high success rate of administration &gt;96% and high compliance in returning symptom sheets &gt;98% add to the credibility of the study reports.

## Adverse events

## Overall incidence of adverse events

## Primary phase

The incidence and nature of symptoms (general v. local) with causal relationship to vaccination are presented in Table 365:

<div style=\"page-break-after: always\"></div>

repuitrlllel

<!-- image -->

During the 8-day follow-up period, at least one symptom (solicited or unsolicited) was reported in 95.6%, 97.5%, 97.1% and 96.2% of subjects in the ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

Grade 3 symptoms were reported in 30.7%, 27.9%, 29.8% and 31.3% of subjects in the ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

<div style=\"page-break-after: always\"></div>

In the ACWY\\_3 group, 24.1% and 14.2% of subjects reported grade 3 symptoms that were general and local, respectively.

In the ACWY\\_2 group, 20.6% and 15.8% of subjects reported grade 3 symptoms that were general and local, respectively.

In the MenCCRM group, 21.3% and 16.3% of subjects reported grade 3 symptoms that were general and local, respectively.

In the MenC-TT group, 24.1% and 17.1% of subjects reported grade 3 symptoms that were general and local, respectively.

At least 91.9% of the subjects reported symptoms that were considered by the investigator to be causally related to vaccination in all four groups.

The reporting of symptoms for the 4-day follow-up was similar to the 8-day follow-up. The majority of the symptoms were reported during the 4-day follow-up.

## Booster and extended safety follow-up phases

The incidence and nature of symptoms with causal relationship to vaccination are presented in Table 410:

<!-- image -->

During the 8-day follow-up period, at least one symptom (solicited or unsolicited) was reported in 88.9%, 85.9%, 88.3% and 87.9% of subjects in the ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

Grade 3 symptoms were reported in 21.9%, 22.7%, 24.7% and 21.9% of subjects in the ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

In the ACWY\\_3 group, 11.7% and 15.1% of the subjects reported grade 3 symptoms that were general and local, respectively.

In the ACWY\\_2 group, 11.9% and 14.1% of subjects reported grade 3 symptoms that were general and local, respectively.

<div style=\"page-break-after: always\"></div>

In the MenCCRM group, 12.5% and 18.1% of subjects reported grade 3 symptoms that were general and local, respetively.

In the MenC-TT group, 13.0% and 13.4% of subjects reported grade 3 symptoms that were general and local, respectively.

At least 80.4% of the symptoms were considered by the investigator to be causally related to vaccination in all four groups.

## Solicited local adverse events

Overall/subject after meningococcal vaccination:

## Primary phase

· Redness was the most frequently reported solicited local symptom in all four groups after meningococcal vaccination during the 8-day post-vaccination period (reported by 45.0% of subjects in the ACWY\\_3 group, 39.4% in the ACWY\\_2 group, 50.1% in the MenCCRM group and 45.0% in the MenC-TT group).

Grade 3 redness was reported in 0.4% of subjects in the ACWY\\_3, MenCCRM and MenC-TT groups and 0.2% in the ACWY\\_2 group.

· Pain was reported in 44.2% of subjects in the ACWY\\_3 group, 38.6% in the ACWY\\_2 group, 41.8% in the MenCCRM group and 41.1% in the MenC-TT group during the 8-day post-vaccination period. Grade 3 pain was reported in 5.6% of subjects in the ACWY\\_3 group, 5.0% in the ACWY\\_2 group, 3.7% in theMenCCRM group and 6.4% in the MenC-TT group.

· Swelling was reported in in 29.7% of subjects in the ACWY\\_3 group, 26.0% in the ACWY\\_2 group, 34.4% in the MenCCRM group and 31.7% in the MenC-TT group during the 8-day postvaccination period.

Grade 3 swelling was reported in 0.2% of subjects in the ACWY\\_3 and ACWY\\_2 groups, 0.6% in the MenCCRM group and 0.8% in the MenC-TT group.

Medical advice was sought by ≤ 0.4% of subjects for any of the local symptoms in all four groups after meningococcal vaccination.

<div style=\"page-break-after: always\"></div>

## Booster and ESFU Phases

· Redness was slightly higher than pain as the most frequently reported solicited local symptom in all four groups during the 8-day post-booster vaccination period (reported by 37.9% of subjects in the ACWY\\_3 group, 43.3% in the ACWY\\_2 group, 42.9% in the MenCCRM group and 45.3% in the MenC-TT group).

Grade 3 redness was reported in 0.6% of subjects in the ACWY\\_3 group, 1.2% in the ACWY\\_2 group, 1.0% in the MenCCRM group and 0.8% in the MenC-TT group.

· Pain was reported in 38.9% of subjects in the ACWY\\_3 group, 39.8% in the ACWY\\_2 group, 40.9% in the MenCCRM group and 36.0% in the MenC-TT group during the 8-day post-booster vaccination period.

Grade 3 pain was reported in 4.9% of subjects in the ACWY\\_3 group, 4.5% in the ACWY\\_2 group, 6.3% in the MenCCRM group and 3.6% in the MenC-TT group.

· Swelling was reported in in 27.1% of subjects in the ACWY\\_3 group, 29.8% in the ACWY\\_2 group, 31.9% in the MenCCRM group and 32.4% in the MenC-TT group during the 8-day postbooster vaccination period.

Grade 3 swelling was reported in 0.2% of subjects in the ACWY\\_3 group, 0.4% in the ACWY\\_2 and MenCCRM groups, and 1.0% in the MenC-TT group.

Medical advice was sought by ≤ 0.2% of subjects for any of the local symptoms in all four groups after meningococcal vaccination.

## Solicited general adverse events

## Primary phase

· Irritability was the most frequently reported solicited general symptom in all four groups during the 8-day post-vaccination period (80.9% of subjects in the ACWY\\_3 group, 83.4% in the ACWY\\_2 group, 86.2% in the MenCCRM group and 85.1% in the MenC-TT group).

Grade 3 irritability was reported in 21.0% of subjects in the ACWY\\_3 group, 15.9% in the ACWY\\_2 group, 16.9% in the MenCCRM group and 20.1% in the MenC-TT group.

· Drowsiness was reported in 72.6% of subjects in the ACWY\\_3 group, 69.8% in the ACWY\\_2 group, 72.7% in the MenCCRM group and 72.8% in the MenC-TT group during the 8-day postvaccination period.

Grade 3 drowsiness was reported in 8.7% of subjects in the ACWY\\_3 group, 7.8% in the ACWY\\_2 group, 7.9% in the MenCCRM group and 9.1% in the MenC-TT group

<div style=\"page-break-after: always\"></div>

- Loss of appetite was reported in 56.9% of subjects in the ACWY\\_3 group, 62.1% in the ACWY\\_2 group, 60.3% in the MenCCRM group and 60.2% in the MenC-TT group during the 8-day postvaccination period.

Grade 3 loss of appetite was reported in 5.4% of subjects in the ACWY\\_3 group, 4.4% in the ACWY\\_2 group, 4.3% in the MenCCRM group and 4.2% in the MenC-TT group.

· Temperature was reported in 52.5% of subjects in the ACWY\\_3 group, 52.4% in the ACWY\\_2 group, 54.4% in the MenCCRM group and 53.1% in the MenC-TT group during the 8-day postvaccination period.

Grade 3 temperature was reported in 0.2% of subjects in the ACWY\\_3 group, 0.4% in the ACWY\\_2 group, 0.6% in the MenCCRM group and 0.4% in the MenC-TT group.

Medical advice was sought by ≤ 3.7% of subjects for any of the general symptoms in all four groups. The most frequent symptom for which medical advice was sought was for temperature.

## Booster and ESFU Phases

· Irritability was the most frequently reported solicited general symptom in all four groups during the 8-day post-booster vaccination period (reported by 57.8% of subjects in the ACWY\\_3 group, 58.0% in the ACWY\\_2 group, 57.3% in the MenCCRM group and 58.9% in the MenC-TT group). Grade 3 irritability was reported in 8.4% of subjects in the ACWY\\_3 group, 7.3% in the ACWY\\_2 group, 7.5% in the MenCCRM group and 8.9% in the MenC-TT group.

- Drowsiness was reported in 40.3% of subjects in the ACWY\\_3 group, 40.4% in the ACWY\\_2 group, 41.9% in the MenCCRM group and 40.1% in the MenC-TT group during the 8-day postbooster vaccination period.

Grade 3 drowsiness was reported in 2.9% of subjects in the ACWY\\_3 group, 2.5% in the ACWY\\_2 group, 4.2% in the MenCCRM group and 3.6% in the MenC-TT group.

- Loss of appetite was reported in in 38.5% of subjects in the ACWY\\_3 group, 37.8% in the ACWY\\_2 group, 39.9% in the MenCCRM group and 38.7% in the MenC-TT group during the 8-day post-booster vaccination period.

Grade 3 loss of appetite was reported in 2.4% of subjects in the ACWY\\_3 group, 4.1% in the ACWY\\_2 group, 4.6% in the MenCCRM group and 5.4% in the MenC-TT group.

- Temperature was reported in in 38.1% of subjects in the ACWY\\_3 group, 35.3% in the ACWY\\_2 group, 37.5% in the MenCCRM group and 33.7% in the MenC-TT group during the 8-day postbooster vaccination period.

Grade 3 temperature was reported in 0.4% of subjects in the ACWY\\_3 group, 0.4% in the ACWY\\_2 group, 0.6% in the MenCCRM group and 1.4% in the MenC-TT group.

<div style=\"page-break-after: always\"></div>

Medical advice was sought by ≤2.9% of subjects for any of the general symptoms in all four groups. Medical advice was most frequently sought for temperature.

## Unsolicited adverse events

## Primary phase

· At least one unsolicited symptom was reported by 55.5 % of subjects in the ACWY\\_3 group, 52.1% in the ACWY\\_2 group, 56.4% in the MenCCRM group and 53.1% in the MenC-TT group during the 31-day post-vaccination period.

Grade 3 unsolicited events were reported in 5.3%, 4.0%, 4.8% and 3.2% of subjects in the ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

The most frequently reported Grade 3 unsolicited events were bronchiolitis, bronchitis, upper respiratory tract infection and gastroenteritis.

· Unsolicited symptoms considered by the investigator to be causally related during 31-day period post-vaccination were reported in 3.8%, 2.3%, 3.3% and 2.8% of subjects in ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

The most common vaccine related symptoms reported were diarrhoea, vomiting and injection site induration.

## Booster and ESFU Phases

At least one unsolicited symptom was reported by 36.0 % of subjects in the ACWY\\_3 group, 36.4% in the ACWY\\_2 group, 32.6% in the MenCCRM group and 32.8% in the MenC-TT group during the 31-day post-booster vaccination period.

Grade 3 unsolicited events were reported in 2.8%, 3.1%, 3.0% and 3.6% of subjects in the ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively. The most frequently reported Grade 3 unsolicited event was gastroenteritis followed by upper respiratory tract infection.

Unsolicited symptoms considered by the investigator to be causally related during 31-day period post-booster vaccination were reported in 0.8%, 1.0%, 1.0% and 0.8% of subjects in ACWY\\_3, ACWY\\_2, MenCCRM and MenC-TT groups, respectively.

The most common vaccine related symptom reported were injection site haematoma and vomiting.

CHMP comment : the overall pattern of adverse symptoms appears similar across all 4 treatment arms.

<div style=\"page-break-after: always\"></div>

## Serious adverse events and deaths

There were not any fatal events in the primary or booster phases.

## Primary phase

The number and percentage of subjects with SAEs classified by MedDRA Primary System Organ Class and Preferred Term reported in the primary phase up to the day preceding the booster dose is presented in Table 381:

CUNFIVCNIIAL

<!-- image -->

<div style=\"page-break-after: always\"></div>

113369(MENACWY-TT-083)

<!-- image -->

113369(MENACWY-TT-083)

Report Final

<!-- image -->

ACWY\\_2 = Subjects who received 2 primary doses of MenACWY-TT at 2 and 4 months of age

ACWY\\_3 = Subjects who received 3 primary doses of MenACWY-TT at 2, 3 and 4 months of age

MenCCRM = Subjects who received 2 primary doses of Menjugate at 2 and 4 months of age

<div style=\"page-break-after: always\"></div>

MenC-TT=Subjectswhoreceived 2primary dosesof NeisVac-Cat 2and4monthsof age At leastone symptom=atleastone symptomexperienced（regardlessof the MedDRAPreferredTerm） N=numberofsubjectswithatleastoneadministered dose n/%=numberpercentageofsubjectsreporting the symptom at leastonce 95%CI=exact95%confidence interval;LL=LowerLimit,UL=UpperLimit

CHMP comment : for serious adverse events, respiratory tract infection and gastroenteritis are notable though appear to occur in all 4 treatment groups. The number of instances is too small to state that these may be more common (or not) upon exposure to the current product.

## Serious Adverse Events from primary vaccination up to end of Extended Safety Follow-Up

Table382

Report Final andPreferredTermfromprimaryvaccinationuptoendofESFU(PrimaryTotalVaccinatedcohort)

Percentage of subjects reportingSerious AdverseEvents classified by MedDRA PrimarySystem Organ Class

<!-- image -->

<div style=\"page-break-after: always\"></div>

1-UOJ

ReportFinal

## 113369(MENACWY-TT-083)

Report Final

<!-- image -->

CUINFIUCINIAL

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

CHMP comment : for serious adverse events, the pattern described for the EFSU is similar to that observed in the primary phase i.e. respiratory tract infection and gastroenteritis. The adverse events are noted but the numbers are considered to be too few to draw conclusions.

## Discontinuation due to AES

## Primary phase

Five subjects withdrew due to an AE or SAE during the primary phase of the study. Two subjects withdrew due to SAEs and one subject withdrew due to an AE in the ACWY\\_3 group, one subject withdrew due to an SAE in the MenCCRM group and one subject withdrew due to an AE in the MenC-TT group.

The three SAEs leading to withdrawal from the study were due to:

- 1) Apparent life threatening illness/Epstein Barr Virus (EBV)
- 2) Muscle spasms
- 3) Respiratory Syncitial Virus (RSV) bronchiolitis

None of these symptoms were determined by the investigators to be causally related to any study vaccination.

## Booster phase

No adverse events led to premature discontinuation of the study in the booster phase.

Comment comment : only 5 subjects withdrew; these withdrawals occurred during the primary phase and were adjudged to be unrelated to the current product. The small number of withdrawals is not likely to affect the overall interpretation of study outcome.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Discussion on clinical aspects

Data submitted by the company are noted.

At this juncture, results submitted by the company suggest that the current product has clinical efficacy in promoting development of antibodies in recipients under 12 months of age against the meningococcus, as described.

Clinical safety results submitted by the company do not appear to raise any particular concern at this juncture.

Questions are not raised within the current procedure.

The company intends to submit a full clinical study report within a forthcoming variation procedure. It is considered that any questions on the clinical study report now submitted will be more appropriately raised during the forthcoming variation procedure.

## 3. Rapporteur's overall conclusion and recommendation

Regulatory action is not required within the current procedure. The company intends to submit a complete study report (within 18 months) in order to undertake a variation procedure and add information to the PI texts. This is acceptable.

It is considered that any questions on the clinical study report now submitted will be more appropriately raised during the forthcoming variation procedure.

## Fulfilled:

Regulatory action is not required within the current procedure.

- [ ] Not fulfilled:

<div style=\"page-break-after: always\"></div>

4. Additional clarification requested

None